

Healthcare Biotechnology Equity – India

Underweight

Target price (INR)	424.00			
Share price (INR)	428.70			
Potential total retu	%) -1.1			
Performance	1M	3M	12M	
Absolute (%)	-7.1	-8.2	17.7	
Relative^ (%)	0.4	-7.2	-4.4	
Index^	BOMBAY SE IDX			
RIC	BION.BO			
Bloomberg	BIOS IN			
Market cap (USDm)		1,038		
Market cap (INRm)		42,870		
Enterprise value (INRm	43443			
Free float (%)	34.7			

20 August 2007

Jatin Kotian * Analyst HSBC Securities and Capital Markets (India) Private Limited +9122 2268 1638 jatinkotian@hsbc.co.in

*Employed by a non-US affiliate of HSBC Securities (USA) Inc, and is not registered/qualified pursuant to NYSE and/or NASD regulations.

Issuer of report: HSBC Securities and Capital Markets (India) Private Limited

Disclaimer & Disclosures.

This report must be read with the disclosures and the analyst certifications in the Disclosure appendix, and with the Disclaimer, that form part of it.

Biocon Ltd

No visible catalysts - retain Underweight rating

- News flow over partnering with Abraxis for launching Biogenerics in US markets only a long term positive
- Absence of credible legislation in the US to accelerate approval timelines for bio generics a key structural negative
- Retain earning estimates and Underweight rating, but raise target price from INR 342 to INR424 per share on rollover of valuation year to FY09 and change in valuation methodology

One small step for entering the US biogenerics market


Biocon had announced a tie-up with Abraxis for launching G-CSF in developed markets, namely the US and Europe. The key highlights of the agreement are:

- Biocon has outlicensed G-CSF to Abraxis for the North American and European markets whereby Abraxis will be responsible for marketing the products in these markets.
- Abraxis will also be responsible for procuring regulatory approvals for the product from the authorities in both geographic regions. Biocon will be responsible for providing the data dossiers to be submitted for regulatory approval.
- Abraxis will bear all expenses for securing regulatory approval and Biocon in turn will get sales royalties once the product is commercialised.

However, regulatory uncertainties still abound


- Unlike chemical molecules, biological drugs require protein characterisation and hence innovator companies have raised questions about whether chemical characterisation of the active substance is sufficient to establish the similarity of a generic product.
- Current pieces of the legislation being piloted in the US are not clear whether:
 a) clinical trials will be required for the biogeneric to be approved. Detailed clinical studies would be expensive and time consuming; b) whether post marketing studies would also be required; these are usually expensive
- Even Europe, which had a head start in framing pathways for biogenerics, now seems to have taken a more cautious approach for such products.





Estimates and valuations

We retain our EPS forecast of INR23.9 for FY08 and INR27.7 for FY09. In addition we now introduce our FY10 estimates where we project EPS of INR29.1. Our earlier valuations for Biocon were derived from DCF based valuations where we assumned cost of equity of 13.5%, explicit forecast period of 3 years, semi-explicit period of 10 years and fade period of 25 years. Based on these assumptions we derived a target price INR342 for Biocon. We now change our valuation methodology to a one year forward EV/EBITDA as we believe that in the absence of any significant medium term drivers the stock is likely to trade in a narrow band. Biocon has traded in a 12-20x one year forward EV/EBITDA band in the last two and a half years and the trading band has further narrowed to 12-16x in the last 18 months.





Given the absence of any significant earning triggers, at least in the medium term, we use the lower end of the trading band i.e. 12x and apply it to our FY09e EBITDA to derive a target price of INR424 per share. Our new target price of INR 424 implies a target PE of 15.2x FY09e EPS (14.3x on FY08 e EPS earlier).

Under our research model, for stocks without a volatility indicator, the Neutral band is five percentage points above and below the hurdle rate for Indian stocks of 11.3%. This translates into a Neutral band of 6.3% to 16.3% around the current share price. Our new 12-month target price of INR424 for Biocon shares suggests a potential total return of -1.1%, which is below the Neutral band. Thus, we retain our Underweight stock rating.

Key risks

- Longer-term drivers are Biocon's fast developing biogeneric capabilities. The key risk to our estimates and rating is some dramatic regulatory changes in the US which would facilitate faster entry of Biogenerics.
- Outlicensing of any molecules under development could also provide earnings and stock price upsides from our current estimates.

Financials & valuation

Financial statements						
Year to	03/2007a	03/2008e	03/2009e	03/2010e		
Profit & loss summary (INR	m)					
Revenue	9,857	10,048	13,184	15,799		
EBITDA	2,835	3,108	3,619	3,773		
Depreciation & amortisation	-665	-572	-602	-602		
Operating profit/EBIT	2,169	2,536	3,018	3,172		
Net interest	-59	66	86	86		
PBT	2,110	2,602	3,104	3,258		
HSBC PBT	0	0	0	C		
Taxation	-169	-208	-325	-341		
Net profit	1,941	2,394	2,778	2,916		
HSBC net profit	1,941	2,394	2,778	2,916		
Cash flow summary (INRm))					
Cash flow from operations	1,568	1,761	2,511	3,046		
Capex	-2,053	-1,664	-1,102	-602		
Cash flow from investment	-1,841	-2,002	-1,044	-603		
Dividends	-441	-662	-882	-309		
Change in net debt	962	-417	-659	-1,593		
FCF equity	-481	220	1,409	2,444		
Balance sheet summary (I	NRm)					
Intangible fixed assets	0	0	0	0		
Tangible fixed assets	9,657	10,750	11,250	11,250		
Current assets	6,086	6,687	7,716	10,210		
Cash & others	878	1,312	1,566	3,160		
Total assets	15,744	17,437	18,966	21,461		
Operating liabilities	2,324	2,368	2,050	2,477		
Gross debt	1,867	1,885	1,480	1,481		
Net debt	990	573	-86	-1,679		
Shareholders funds	10,692	12,424	14,320	16,354		
Invested capital	12,542	13,757	15,350	15,823		

Valuation data						
Year to	03/2007a	03/2008e	03/2009e	03/2010e		
EV/sales	4.4	4.3	3.2	2.6		
EV/EBITDA	15.5	14.0	11.8	10.9		
EV/IC	3.5	3.2	2.8	2.6		
PE*	22.1	17.9	15.4	14.7		
P/NAV	4.0	3.5	3.0	2.6		
FCF yield (%)	-1.1	0.5	3.3	5.7		
Dividend yield (%)	0.9	1.4	1.9	0.7		

Note: * = Based on HSBC EPS (fully diluted)



Note: price at close of 17 Aug 2007

Ratio, growth and per share analysis

Year to	03/2007a	03/2008e	03/2009e	03/2010e
Y-o-y % change				
Revenue	25.1	1.9	31.2	19.8
EBITDA	23.9	9.6	16.4	4.3
Operating profit	8.9	16.9	19.0	5.1
PBT	4.2	23.3	19.3	5.0
HSBC EPS	12.8	23.3	16.1	5.0
Ratios (%)				
Revenue/IC (x)	0.9	0.8	0.9	1.0
ROIC	18.0	17.7	18.6	18.2
ROE	19.8	20.7	20.8	19.0
ROA	14.2	15.0	15.6	14.8
EBITDA margin	28.8	30.9	27.5	23.9
Operating profit margin	22.0	25.2	22.9	20.1
EBITDA/net interest (x)	47.7			
Net debt/equity	9.3	4.6	-0.6	-10.3
Net debt/EBITDA (x)	0.3	0.2	0.0	-0.4
CF from operations/net debt	158.4	307.2		
Per share data (INR)				
EPS reported (fully diluted)	19.41	23.94	27.78	29.16
HSBC EPS (fully diluted)	19.41	23.94	27.78	29.16
DPS	4.00	6.00	8.00	3.09
NAV	106.92	124.24	143.20	163.54



Disclosure appendix

Analyst certification

The following analyst(s), who is(are) primarily responsible for this report, certifies(y) that the opinion(s) on the subject security(ies) or issuer(s) and any other views or forecasts expressed herein accurately reflect their personal view(s) and that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report: Jatin Kotian

Important disclosures

Stock ratings and basis for financial analysis

HSBC believes that investors utilise various disciplines and investment horizons when making investment decisions, which depend largely on individual circumstances such as the investor's existing holdings, risk tolerance and other considerations. Given these differences, HSBC has two principal aims in its equity research: 1) to identify long-term investment opportunities based on particular themes or ideas that may affect the future earnings or cash flows of companies on a 12 month time horizon; and 2) from time to time to identify short-term investment opportunities that are derived from fundamental, quantitative, technical or event-driven techniques on a 0-3 month time horizon and which may differ from our long-term investment rating. HSBC has assigned ratings for its long-term investment opportunities as described below.

This report addresses only the long-term investment opportunities of the companies referred to in the report. As and when HSBC publishes a short-term trading idea the stocks to which these relate are identified on the website at www.hsbcnet.com/research. Details of these short-term investment opportunities can be found under the Reports section of this website.

HSBC believes an investor's decision to buy or sell a stock should depend on individual circumstances such as the investor's existing holdings and other considerations. Different securities firms use a variety of ratings terms as well as different rating systems to describe their recommendations. Investors should carefully read the definitions of the ratings used in each research report. In addition, because research reports contain more complete information concerning the analysts' views, investors should carefully read the entire research report and should not infer its contents from the rating. In any case, ratings should not be used or relied on in isolation as investment advice.

Rating definitions for long-term investment opportunities

Stock ratings

HSBC assigns ratings to its stocks in this sector on the following basis:

For each stock we set a required rate of return calculated from the risk free rate for that stock's domestic, or as appropriate, regional market and the relevant equity risk premium established by our strategy team. The price target for a stock represents the value the analyst expects the stock to reach over our performance horizon. The performance horizon is 12 months. For a stock to be classified as Overweight, the implied return must exceed the required return by at least 5 percentage points over the next 12 months (or 10 percentage points for a stock classified as Volatile*). For a stock to be classified as Underweight, the stock must be expected to underperform its required return by at least 5 percentage points over the next 12 months (or 10 percentage as Volatile*). Stocks between these bands are classified as Neutral.

Our ratings are re-calibrated against these bands at the time of any 'material change' (initiation of coverage, change of volatility status or change in price target). Notwithstanding this, and although ratings are subject to ongoing management review, expected returns will be permitted to move outside the bands as a result of normal share price fluctuations without necessarily triggering a rating change.



*A stock will be classified as volatile if its historical volatility has exceeded 40%, if the stock has been listed for less than 12 months (unless it is in an industry or sector where volatility is low) or if the analyst expects significant volatility. However, stocks which we do not consider volatile may in fact also behave in such a way. Historical volatility is defined as the past month's average of the daily 365-day moving average volatilities. In order to avoid misleadingly frequent changes in rating, however, volatility has to move 2.5 percentage points past the 40% benchmark in either direction for a stock's status to change.

Prior to this, from 7 June 2005 HSBC applied a ratings structure which ranked the stocks according to their notional target price vs current market price and then categorised (approximately) the top 40% as Overweight, the next 40% as Neutral and the last 20% as Underweight. The performance horizon is 2 years. The notional target price was defined as the mid-point of the analysts' valuation for a stock.

From 15 November 2004 to 7 June 2005, HSBC carried no ratings and concentrated on long-term thematic reports which identified themes and trends in industries, but did not make a conclusion as to the investment action that potential investors should take.


Prior to 15 November 2004, HSBC's ratings system was based upon a two-stage recommendation structure: a combination of the analysts' view on the stock relative to its sector and the sector call relative to the market, together giving a view on the stock relative to the market. The sector call was the responsibility of the strategy team, set in co-operation with the analysts. For other companies, HSBC showed a recommendation relative to the market. The performance horizon was 6-12 months. The target price was the level the stock should have traded at if the market accepted the analysts' view of the stock.

Rating distribution for long-term investment opportunities

As of 20 August 2007, the distribution of all ratings published is as follows:

Overweight (Buy)	46%	(24% of these provided with Investment Banking Services)
Neutral (Hold)	35%	(24% of these provided with Investment Banking Services)
Underweight (Sell)	19%	(18% of these provided with Investment Banking Services)

Share price and rating changes for long-term investment opportunities



То		
10	Date	
N/R	15 November 2004	
Overweight	08 July 2005	
Neutral	29 November 2005	
Overweight	21 April 2006	
Neutral	20 July 2006	
Underweight	18 October 2006	
Value	Date	
N/R	15 November 2004	
492.00	08 July 2005	
570.00	29 September 2005	
462.00	29 November 2005	
550.00	21 April 2006	
378.00	20 July 2006	
342.00	18 October 2006	
	Overweight Neutral Overweight Neutral Underweight Value N/R 492.00 570.00 462.00 550.00 378.00	



HSBC & Analyst disclosures

Disclosure checklist					
Company	Ticker	Recent price	Price Date	Disclosure	
BIOCON LIMITED	BION.NS	428.70	17-Aug-2007	6	
	BION.NS	420.70	17-Aug-2007		

Source: HSBC

- 1 HSBC* has managed or co-managed a public offering of securities for this company within the past 12 months.
- 2 HSBC expects to receive or intends to seek compensation for investment banking services from this company in the next 3 months.
- 3 At the time of publication of this report, HSBC is a market maker in securities issued by this company.
- 4 As of 31 July 2007 HSBC beneficially owned 1% or more of a class of common equity securities of this company.
- 5 As of 30 June 2007, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of investment banking services.
- 6 As of 30 June 2007, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-investment banking-securities related services.
- 7 As of 30 June 2007, this company was a client of HSBC or had during the preceding 12 month period been a client of and/or paid compensation to HSBC in respect of non-securities services.
- 8 A covering analyst/s has received compensation from this company in the past 12 months.
- 9 A covering analyst/s or a member of his/her household has a financial interest in the securities of this company, as detailed below.
- 10 A covering analyst/s or a member of his/her household is an officer, director or supervisory board member of this company, as detailed below.

Analysts are paid in part by reference to the profitability of HSBC which includes investment banking revenues.

For disclosures in respect of any company, please see the most recently published report on that company available at www.hsbcnet.com/research.

* HSBC Legal Entities are listed in the Disclaimer below.

Additional disclosures

- 1 This report is dated as at 20 August 2007.
- 2 All market data included in this report are dated as at close 17 August 2007, unless otherwise indicated in the report.
- 3 HSBC has procedures in place to identify and manage any potential conflicts of interest that arise in connection with its Research business. HSBC's analysts and its other staff who are involved in the preparation and dissemination of Research operate and have a management reporting line independent of HSBC's Investment Banking business. Chinese Wall procedures are in place between the Investment Banking and Research businesses to ensure that any confidential and/or price sensitive information is handled in an appropriate manner.



Disclaimer

* Legal entities as at 24 July 2007

[']UAE' HSBC Bank Middle East Limited, Dubai; 'HK' The Hongkong and Shanghai Banking Corporation Limited, Hong Kong; 'TW' HSBC Securities (Asia) Limited, Taipei Branch; 'CA' HSBC Securities (Canada) Inc, Toronto; HSBC Bank, Paris branch; HSBC France; 'DE' HSBC Trinkaus & Burkhardt AG, Dusseldorf; 000 HSBC Bank (RR), Moscow; 'IN' HSBC Securities and Capital Markets (India) Private Limited, Mumbai; 'JP' HSBC Securities (Japan) Limited, Tokyo; 'EG' HSBC Securities Egypt S.A.E., Cairo; 'CN' HSBC Investment Bank Asia Limited, Beijing Representative Office; The Hongkong and Shanghai Banking Corporation Limited, Singapore branch; The Hongkong and Shanghai Banking Corporation Limited, Securities S.A., Athens; HSBC Bank plc, London, Madrid, Milan, Stockholm, Tel Aviv, 'US' HSBC Securities (USA) Inc, New York; HSBC Yatirim Menkul Degerler A.S., Istanbul; HSBC México, S.A., Institución de Banca Múltiple, Grupo Financiero HSBC, HSBC Bank Brasil S.A. -Banco Múltiplo. Issuer of report HSBC Securities and Capital Markets (India) Private Limited Registered Office 52/60 Mahatma Gandhi Road Fort, Mumbai 400 001, India Telephone: +91 22 2267 4921 Fax: +91 22 2263 1983 Website: www.hsbcnet.com/research

This document has been issued by HSBC Securities and Capital Markets (India) Private Limited ("HSBC") for the information of its customers only. HSBC Securities and Capital Markets (India) Private Limited is regulated by the Securities and Exchange Board of India. If it is received by a customer of an affiliate of HSBC, its provision to the recipient is subject to the terms of business in place between the recipient and such affiliate. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. HSBC has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; HSBC makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the Research Division of HSBC only and are subject to change without notice. HSBC and its affiliates and/or their officers, directors and employees may have positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). HSBC and its affiliates may act as market maker or have assumed an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform investment banking or underwriting services for or relating to those companies and may also be represented in the supervisory board or any other committee of those companies. The information and opinions contained within the research reports are based upon publicly available information and rates of taxation applicable at the time of publication which are subject to change from time to time. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Where an investment is denominated in a currency other than the local currency of the recipient of the research report, changes in the exchange rates may have an adverse effect on the value, price or income of that investment. In case of investments for which there is no recognised market it may be difficult for investors to sell their investments or to obtain reliable information about its value or the extent of the risk to which it is exposed.

HSBC Securities (USA) Inc. accepts responsibility for the content of this research report prepared by its non-US foreign affiliate. All U.S. persons receiving and/or accessing this report and wishing to effect transactions in any security discussed herein should do so with HSBC Securities (USA) Inc. in the United States and not with its non-US foreign affiliate, the issuer of this report.

In the UK this report may only be distributed to persons of a kind described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001. The protections afforded by the UK regulatory regime are available only to those dealing with a representative of HSBC Bank plc in the UK. In Singapore, this publication is distributed by The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch for the general information of institutional investors or other persons specified in Sections 274 and 304 of the Securities and Futures Act (Chapter 289) ("SFA") and accredited investors and other persons in accordance with the conditions specified in Sections 275 and 305 of the SFA. This publication is not a prospectus as defined in the SFA. It may not be further distributed in whole or in part for any purpose. The Hongkong and Shanghai Banking Corporation Limited Singapore Branch is regulated by the Monetary Authority of Singapore. In Australia, this publication has been distributed by HSBC Stockbroking (Australia) Pty Limited (ABN 60 007 114 605) for the general information of its "wholesale" customers (as defined in the Corporations Act 2001). It makes no representations that the products or services mentioned in this document are available to persons in Australia or are necessarily suitable for any particular person or appropriate in accordance with local law. No consideration has been given to the particular investment objectives, financial situation or particular needs of any recipient. In Japan, this publication has been distributed by HSBC Securities (Japan) Limited. In Hong Kong, this document has been distributed by The Hongkong and Shanghai Banking Corporation Limited in the conduct of its Hong Kong regulated business for the information of its institutional and professional customers; it is not intended for and should not be distributed to retail customers in Hong Kong. The Hongkong and Shanghai Banking Corporation Limited makes no representations that the products or services mentioned in this document are available to persons in Hong Kong or are necessarily suitable for any particular person or appropriate in accordance with local law. All inquiries by such recipients must be directed to The Hongkong and Shanghai Banking Corporation Limited. © Copyright. HSBC Securities and Capital Markets (India) Private Limited 2007, ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, on any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of HSBC Securities and Capital Markets (India) Private Limited. (March 2005)

MICA (P) 316/06/2007